Mobidiag Ltd today announced the issuance of two new patents covering a method and a kit for detecting antibiotic resistant bacteria, and more specifically, screening for carbapenemase genes causing carbapenem resistance in bacteria.
Mobidiag sera présent lors des JFHOD (Journées Francophones d’Hépato-gastroentérologie et d’Oncologie Digestive), congrès francophone de référence des maladies et cancers de l’appareil digestif. L’évènement se tiendra à Paris au Palais des congrès – Porte Maillot, les 23-26 mars.
Mobidiag will be attending the Dansk Selskab for Klinisk Mikrobiologi årsmøde, which will take place in Nyborg, Denmark, March 10-11, 2017.
Mobidiag Ltd today announced the CE-IVD marking of Amplidiag® Easy, a proprietary system allowing nucleic acid extraction and PCR setup directly from stool samples. The Amplidiag® Easy provides users with an automated solution accelerating the sample to result time.
Mobidiag sera présent lors de la 25ème Journée d’Actualités consacrée aux bactéries du genre Helicobacter. L’évènement, organisé par le GEFH (Groupe d’Etudes Français des Helicobacter), se tiendra à Paris à l’Hôpital Cochin, le 27 janvier 2017.
Mobidiag Ltd today announced that it will offer the Amplidiag® product line in South Africa through a distribution agreement with PerkinElmer® Inc.’s Wallac Oy subsidiary. The Amplidiag® product line includes in vitro diagnostic tests and compatible systems for the detection of gastrointestinal infections.
Mobidiag will be attending the Kliinisen mikrobiologian kiertokoulu (Microbiology education days) in Turku, Finland, November 18, 2016. Contact us to arrange a meeting with us during the event or meet us directly at our booth.
This one page article presents Mobidiag and explains how innovative molecular diagnostics can help avoid unneccessary use of antibiotics and enable a quicker and more accurate treatment decision. Read full article here
Mobidiag announces an agreement with YouMed for the commercialization in UK of Amplidiag® product line, in vitro diagnostic tests and compatible system for the detection of gastrointestinal infections.
Mobidiag announces an agreement with Bioportugal Química Farmacêutica Lda, expert provider of products for the life science market (diagnostics, pharmaceutical, hospital furniture and equipment), for the distribution of the Amplidiag® product line. Under this agreement Bioportugal becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Portugal.
Mobidiag has announced an agreement with Biomedica Medizinprodukte GmbH & Co KG, provider of a large panel of medical products for health professionals, medical scientists, and research laboratories, for the distribution of the Amplidiag® product line.
We announce today the launch of our CE-IVD marked Amplidiag® Stool Parasites kit, a molecular test allowing detection of the main diarrhea causing stool parasites simultaneously directly from patient stool samples.
As part of the InnovFin initiative, the loan will allow Mobidiag to finalize and scale up Novodiag® products manufacturing, assay validation and commercialization over the next 3 years.
We are pleased to announce that under this new agreement Isogen becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Belgium, the Netherlands, Luxembourg and Spain.
The 36th Interdisciplinary Meeting of Anti-Infective Chemotherapy (RICAI) gathers together French-speaking microbiologists and infectious diseases specialists. The event will be held at Palais des Congrès de Paris, from Monday 12th to Tuesday 13th of December 2016.